Safety, tolerance and antiretroviral activity of IMP: a pilot clinical trial in patients with recent HIV-1 infection

Korábbi kezelés

• -Ongoing or previous pleural effusion
• -Any concomitant treatment with potentially dangerous drug interaction with dasatinib.
• -Any clinical condition, at the opinion of the investigator, contraindicating participation (for example, active neoplastic disease, active concomitant infection, etc.)

Más betegség

• -Active HBV (HBsAg+ or DNA+) and/or HCV (RNA+) infection on screening.
• -Chronic obstructive pulmonary disease, bronchial asthma or recent chest trauma.
• -History of gastrointestinal or other bleeding.

Laborértékek

• -ALT> 2 UNL, glomerular filtration rate <70 mL / 1.73 m2, leukocytes <4000 / mm3, total lymphocyte count <1000 / mm3, platelets <100,000 / mm3 or Hg <12g / dL.

Egyéb

• -Pregnancy or active breastfeeding

• -Age range: 18 to 65 years.
• -Documented asymptomatic HIV-1 infection of more than 3 months duration (all patients must have a positive Western blot, including the p31 band, indicating an infection of more than 90 days duration).
• -Not having received ART.
• -CD4 T lymphocyte count > 350 / μl.
• -Patient giving written informed consent.